










<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/css" href="http://52.214.119.220/wiki/skins/common/feed.css?97"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/">
	<channel>
		<title>5ugl - Revision history</title>
		<link>http://52.214.119.220/wiki/index.php?title=5ugl&amp;action=history</link>
		<description>Revision history for this page on the wiki</description>
		<language>en</language>
		<generator>MediaWiki 1.11.2</generator>
		<lastBuildDate>Mon, 06 Apr 2026 11:00:25 GMT</lastBuildDate>
		<item>
			<title>OCA at 13:27, 4 October 2023</title>
			<link>http://52.214.119.220/wiki/index.php?title=5ugl&amp;diff=3891930&amp;oldid=prev</link>
			<description>&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 13:27, 4 October 2023&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 3:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 3:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='5ugl' size='340' side='right'caption='[[5ugl]], [[Resolution|resolution]] 1.86&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='5ugl' size='340' side='right'caption='[[5ugl]], [[Resolution|resolution]] 1.86&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[5ugl]] is a 2 chain structure with sequence from [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://en.wikipedia.org/wiki/&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Human Human&lt;/del&gt;]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5UGL OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;oca&lt;/del&gt;.&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;weizmann.ac.il/oca-docs&lt;/del&gt;/fgij/fg.htm?mol=5UGL FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[5ugl]] is a 2 chain structure with sequence from [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://en.wikipedia.org/wiki/&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Homo_sapiens Homo sapiens&lt;/ins&gt;]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5UGL OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;proteopedia&lt;/ins&gt;.&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;org&lt;/ins&gt;/fgij/fg.htm?mol=5UGL FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;ligand&lt;/del&gt;'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Ligand&lt;/del&gt;|&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Ligands&lt;/del&gt;:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;gt;&amp;lt;scene name='pdbligand=ANP:PHOSPHOAMINOPHOSPHONIC+ACID-ADENYLATE+ESTER'&amp;gt;ANP&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=SO4:SULFATE+ION'&amp;gt;SO4&amp;lt;/scene&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;method&lt;/ins&gt;'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Empirical_models&lt;/ins&gt;|&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Method&lt;/ins&gt;:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot; id=&amp;quot;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;methodDat&lt;/ins&gt;&amp;quot;&amp;gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;X-ray diffraction&lt;/ins&gt;, [[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Resolution&lt;/ins&gt;|&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Resolution&lt;/ins&gt;]] &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;1.861&amp;amp;#8491;&lt;/ins&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr &lt;/del&gt;id&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;='related'&amp;gt;&amp;lt;td class&lt;/del&gt;=&amp;quot;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;sblockLbl&lt;/del&gt;&amp;quot;&amp;gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;b&amp;gt;[[Related_structure|Related:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;[[5ui0|5ui0]]&lt;/del&gt;, [[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;5ugx&lt;/del&gt;|&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;5ugx]], [[5uhn|5uhn&lt;/del&gt;]]&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;ligand&lt;/ins&gt;'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Ligand&lt;/ins&gt;|&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Ligands&lt;/ins&gt;:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot; id=&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;quot;ligandDat&amp;quot;&lt;/ins&gt;&amp;gt;&amp;lt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;scene name&lt;/ins&gt;='&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;pdbligand&lt;/ins&gt;=&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;ANP&lt;/ins&gt;:&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;PHOSPHOAMINOPHOSPHONIC+ACID-ADENYLATE+ESTER'&lt;/ins&gt;&amp;gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;ANP&lt;/ins&gt;&amp;lt;/&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;scene&lt;/ins&gt;&amp;gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;, &lt;/ins&gt;&amp;lt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;scene name&lt;/ins&gt;=&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;'pdbligand&lt;/ins&gt;=&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;SO4:SULFATE+ION&lt;/ins&gt;'&amp;gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;SO4&lt;/ins&gt;&amp;lt;/&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;scene&lt;/ins&gt;&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;gene&lt;/del&gt;'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Gene&lt;/del&gt;|&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Gene&lt;/del&gt;:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;gt;FGFR2, BEK, KGFR, KSAM ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;amp;srchmode=5&amp;amp;&lt;/del&gt;id=&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;9606 HUMAN])&amp;lt;/td&lt;/del&gt;&amp;gt;&amp;lt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;/tr&amp;gt;&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;proteopedia&lt;/ins&gt;.&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;org&lt;/ins&gt;/fgij/fg.htm?mol=5ugl FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5ugl OCA], [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://pdbe.org/5ugl PDBe], [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://www.rcsb.org/pdb/explore.do?structureId=5ugl RCSB], [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://www.ebi.ac.uk/pdbsum/5ugl PDBsum], [&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://prosat.h-its.org/prosat/prosatexe?pdbcode=5ugl ProSAT]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr id&lt;/del&gt;='&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;activity'&amp;gt;&amp;lt;td class&lt;/del&gt;=&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Activity&lt;/del&gt;:&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;/b&lt;/del&gt;&amp;gt;&amp;lt;/&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;td&lt;/del&gt;&amp;gt;&amp;lt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;td class&lt;/del&gt;=&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class&lt;/del&gt;=&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;'plainlinks&lt;/del&gt;'&amp;gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] &lt;/del&gt;&amp;lt;/&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;span&lt;/del&gt;&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;oca&lt;/del&gt;.&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;weizmann.ac.il/oca-docs&lt;/del&gt;/fgij/fg.htm?mol=5ugl FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5ugl OCA], [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://pdbe.org/5ugl PDBe], [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://www.rcsb.org/pdb/explore.do?structureId=5ugl RCSB], [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://www.ebi.ac.uk/pdbsum/5ugl PDBsum], [&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://prosat.h-its.org/prosat/prosatexe?pdbcode=5ugl ProSAT]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/table&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/table&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Disease ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Disease ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[http&lt;/del&gt;://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;] Defects in FGFR2 are the cause of Crouzon syndrome (CS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/123500 123500&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]; also called craniofacial dysostosis type I (CFD1). CS is an autosomal dominant syndrome characterized by craniosynostosis (premature fusion of the skull sutures), hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; [:]&amp;lt;ref&amp;gt;PMID:7581378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7987400&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7655462&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8946174&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8956050&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9152842&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9521581&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10574673&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11380921&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Jackson-Weiss syndrome (JWS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/123150 123150&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]. JWS is an autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9385368&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Apert syndrome (APRS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/101200 101200&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]; also known as acrocephalosyndactyly type 1 (ACS1). APRS is a syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. The craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations.&amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7668257&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11390973&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719344&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9452027&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Pfeiffer syndrome (PS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/101600 101600&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly. Three subtypes of Pfeiffer syndrome have been described: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).&amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719333&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719345&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9150725&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9693549&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9719378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10394936&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10945669&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Beare-Stevenson cutis gyrata syndrome (BSCGS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/123790 123790&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]. BSCGS is an autosomal dominant condition is characterized by the furrowed skin disorder of cutis gyrata, acanthosis nigricans, craniosynostosis, craniofacial dysmorphism, digital anomalies, umbilical and anogenital abnormalities and early death.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8696350&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12000365&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of familial scaphocephaly syndrome (FSPC) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/609579 609579&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]; also known as scaphocephaly with maxillary retrusion and mental retardation. FSPC is an autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16061565&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/149730 149730&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18056630&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16501574&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis (ABS2) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/207410 207410&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]. A rare syndrome characterized by craniosynostosis, radiohumeral synostosis present from the perinatal period, midface hypoplasia, choanal stenosis or atresia, femoral bowing and multiple joint contractures. Arachnodactyly and/or camptodactyly have also been reported.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10633130&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Bent bone dysplasia syndrome (BBDS) [MIM:[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;http&lt;/del&gt;://omim.org/entry/614592 614592&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;]. BBDS is a perinatal lethal skeletal dysplasia characterized by poor mineralization of the calvarium, craniosynostosis, dysmorphic facial features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, and bent long bones. Dysmorphic facial features included low-set ears, hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and micrognathia.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:22387015&amp;lt;/ref&amp;gt; &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt; &lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN] Defects in FGFR2 are the cause of Crouzon syndrome (CS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/123500 123500]; also called craniofacial dysostosis type I (CFD1). CS is an autosomal dominant syndrome characterized by craniosynostosis (premature fusion of the skull sutures), hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; [:]&amp;lt;ref&amp;gt;PMID:7581378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7987400&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7655462&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8946174&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8956050&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9152842&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9521581&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10574673&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11380921&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Jackson-Weiss syndrome (JWS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/123150 123150]. JWS is an autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9385368&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Apert syndrome (APRS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/101200 101200]; also known as acrocephalosyndactyly type 1 (ACS1). APRS is a syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. The craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations.&amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7668257&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11390973&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719344&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9452027&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Pfeiffer syndrome (PS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/101600 101600]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly. Three subtypes of Pfeiffer syndrome have been described: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).&amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719333&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719345&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9150725&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9693549&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9719378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10394936&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10945669&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Beare-Stevenson cutis gyrata syndrome (BSCGS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/123790 123790]. BSCGS is an autosomal dominant condition is characterized by the furrowed skin disorder of cutis gyrata, acanthosis nigricans, craniosynostosis, craniofacial dysmorphism, digital anomalies, umbilical and anogenital abnormalities and early death.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8696350&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12000365&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of familial scaphocephaly syndrome (FSPC) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/609579 609579]; also known as scaphocephaly with maxillary retrusion and mental retardation. FSPC is an autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16061565&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/149730 149730]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18056630&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16501574&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis (ABS2) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/207410 207410]. A rare syndrome characterized by craniosynostosis, radiohumeral synostosis present from the perinatal period, midface hypoplasia, choanal stenosis or atresia, femoral bowing and multiple joint contractures. Arachnodactyly and/or camptodactyly have also been reported.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10633130&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Bent bone dysplasia syndrome (BBDS) [MIM:[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://omim.org/entry/614592 614592]. BBDS is a perinatal lethal skeletal dysplasia characterized by poor mineralization of the calvarium, craniosynostosis, dysmorphic facial features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, and bent long bones. Dysmorphic facial features included low-set ears, hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and micrognathia.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:22387015&amp;lt;/ref&amp;gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Function ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Function ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[http&lt;/del&gt;://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]&lt;/del&gt;] Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.&amp;lt;ref&amp;gt;PMID:8961926&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8663044&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12529371&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15629145&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16597617&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17623664&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17311277&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18374639&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19410646&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19103595&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:21596750&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16384934&amp;lt;/ref&amp;gt; &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt; &lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;https&lt;/ins&gt;://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN] Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.&amp;lt;ref&amp;gt;PMID:8961926&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8663044&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12529371&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15629145&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16597617&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17623664&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17311277&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18374639&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19410646&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19103595&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:21596750&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16384934&amp;lt;/ref&amp;gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;div style=&amp;quot;background-color:#fffaf0;&amp;quot;&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;div style=&amp;quot;background-color:#fffaf0;&amp;quot;&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Publication Abstract from PubMed ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Publication Abstract from PubMed ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 30:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 28:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;__TOC__&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;__TOC__&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/StructureSection&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/StructureSection&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Human&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Homo sapiens&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Large Structures]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Large Structures]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen H]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;, &lt;/del&gt;H]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Mohammadi M]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Mohammadi&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;, &lt;/del&gt;M&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Atp analoge]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Gain-of-function mutation]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Transferase]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category: Tyrosine kinase domain&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
			<pubDate>Wed, 04 Oct 2023 13:27:14 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:5ugl</comments>		</item>
		<item>
			<title>OCA at 17:07, 11 December 2019</title>
			<link>http://52.214.119.220/wiki/index.php?title=5ugl&amp;diff=3125222&amp;oldid=prev</link>
			<description>&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 17:07, 11 December 2019&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==Crystal Structure of FGF Receptor 2 Tyrosine Kinase Domain Harboring the D650V Activating Mutation==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==Crystal Structure of FGF Receptor 2 Tyrosine Kinase Domain Harboring the D650V Activating Mutation==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='5ugl' size='340' side='right' caption='[[5ugl]], [[Resolution|resolution]] 1.86&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;StructureSection load='5ugl' size='340' side='right'caption='[[5ugl]], [[Resolution|resolution]] 1.86&amp;amp;Aring;' scene=''&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== Structural highlights ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[5ugl]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5UGL OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5UGL FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[5ugl]] is a 2 chain structure &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;with sequence from [http://en.wikipedia.org/wiki/Human Human]&lt;/ins&gt;. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5UGL OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5UGL FirstGlance]. &amp;lt;br&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='ligand'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Ligand|Ligands:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;scene name='pdbligand=ANP:PHOSPHOAMINOPHOSPHONIC+ACID-ADENYLATE+ESTER'&amp;gt;ANP&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=SO4:SULFATE+ION'&amp;gt;SO4&amp;lt;/scene&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='ligand'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Ligand|Ligands:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;scene name='pdbligand=ANP:PHOSPHOAMINOPHOSPHONIC+ACID-ADENYLATE+ESTER'&amp;gt;ANP&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=SO4:SULFATE+ION'&amp;gt;SO4&amp;lt;/scene&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='related'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Related_structure|Related:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;[[5ui0|5ui0]], [[5ugx|5ugx]], [[5uhn|5uhn]]&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='related'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Related_structure|Related:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;[[5ui0|5ui0]], [[5ugx|5ugx]], [[5uhn|5uhn]]&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='gene'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Gene|Gene:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;FGFR2, BEK, KGFR, KSAM ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;amp;srchmode=5&amp;amp;id=9606 HUMAN])&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='activity'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Activity:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] &amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='activity'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Activity:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] &amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5ugl FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5ugl OCA], [http://pdbe.org/5ugl PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5ugl RCSB], [http://www.ebi.ac.uk/pdbsum/5ugl PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5ugl ProSAT]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5ugl FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5ugl OCA], [http://pdbe.org/5ugl PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5ugl RCSB], [http://www.ebi.ac.uk/pdbsum/5ugl PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5ugl ProSAT]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 22:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 23:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;div class=&amp;quot;pdbe-citations 5ugl&amp;quot; style=&amp;quot;background-color:#fffaf0;&amp;quot;&amp;gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;div class=&amp;quot;pdbe-citations 5ugl&amp;quot; style=&amp;quot;background-color:#fffaf0;&amp;quot;&amp;gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==See Also==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;*[[Fibroblast growth factor receptor 3D receptor|Fibroblast growth factor receptor 3D receptor]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;__TOC__&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;__TOC__&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/StructureSection&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/StructureSection&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Human]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Large Structures]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Receptor protein-tyrosine kinase]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen, H]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen, H]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
			<pubDate>Wed, 11 Dec 2019 17:07:31 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:5ugl</comments>		</item>
		<item>
			<title>OCA at 14:33, 6 November 2017</title>
			<link>http://52.214.119.220/wiki/index.php?title=5ugl&amp;diff=2805348&amp;oldid=prev</link>
			<description>&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 14:33, 6 November 2017&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 22:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 22:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;div class=&amp;quot;pdbe-citations 5ugl&amp;quot; style=&amp;quot;background-color:#fffaf0;&amp;quot;&amp;gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;div class=&amp;quot;pdbe-citations 5ugl&amp;quot; style=&amp;quot;background-color:#fffaf0;&amp;quot;&amp;gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==See Also==&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;*[[Fibroblast growth factor receptor|Fibroblast growth factor receptor]]&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
			<pubDate>Mon, 06 Nov 2017 14:33:45 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:5ugl</comments>		</item>
		<item>
			<title>OCA at 09:58, 27 September 2017</title>
			<link>http://52.214.119.220/wiki/index.php?title=5ugl&amp;diff=2767956&amp;oldid=prev</link>
			<description>&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 09:58, 27 September 2017&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 22:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 22:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;div class=&amp;quot;pdbe-citations 5ugl&amp;quot; style=&amp;quot;background-color:#fffaf0;&amp;quot;&amp;gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;div class=&amp;quot;pdbe-citations 5ugl&amp;quot; style=&amp;quot;background-color:#fffaf0;&amp;quot;&amp;gt;&amp;lt;/div&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;==See Also==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;*[[Fibroblast growth factor receptor|Fibroblast growth factor receptor]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;== References ==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&amp;lt;references/&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
			<pubDate>Wed, 27 Sep 2017 09:58:50 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:5ugl</comments>		</item>
		<item>
			<title>OCA at 01:43, 11 March 2017</title>
			<link>http://52.214.119.220/wiki/index.php?title=5ugl&amp;diff=2727305&amp;oldid=prev</link>
			<description>&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 01:43, 11 March 2017&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;'''Unreleased structure'''&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;The entry &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;5ugl &lt;/del&gt;is &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;ON HOLD &lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;==Crystal Structure of FGF Receptor 2 Tyrosine Kinase Domain Harboring the D650V Activating Mutation==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;StructureSection load='5ugl' size='340' side='right' caption='[[5ugl]], [[Resolution|resolution]] 1.86&amp;amp;Aring;' scene=''&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;== Structural highlights ==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;table&amp;gt;&amp;lt;tr&amp;gt;&amp;lt;td colspan='2'&amp;gt;[[5ugl]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5UGL OCA]. For a &amp;lt;b&amp;gt;guided tour on the structure components&amp;lt;/b&amp;gt; use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5UGL FirstGlance]. &amp;lt;br&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&amp;lt;tr id='ligand'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Ligand|Ligands:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;scene name='pdbligand=ANP:PHOSPHOAMINOPHOSPHONIC+ACID-ADENYLATE+ESTER'&amp;gt;ANP&amp;lt;/scene&amp;gt;, &amp;lt;scene name='pdbligand=SO4:SULFATE+ION'&amp;gt;SO4&amp;lt;/scene&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr id='related'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;[[Related_structure|Related:]]&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;[[5ui0|5ui0]], [[5ugx|5ugx]], [[5uhn|5uhn]]&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr id='activity'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Activity:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] &amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;tr id='resources'&amp;gt;&amp;lt;td class=&amp;quot;sblockLbl&amp;quot;&amp;gt;&amp;lt;b&amp;gt;Resources:&amp;lt;/b&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;td class=&amp;quot;sblockDat&amp;quot;&amp;gt;&amp;lt;span class='plainlinks'&amp;gt;[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5ugl FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5ugl OCA], [http://pdbe.org/5ugl PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5ugl RCSB], [http://www.ebi.ac.uk/pdbsum/5ugl PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5ugl ProSAT]&amp;lt;/span&amp;gt;&amp;lt;/td&amp;gt;&amp;lt;/tr&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;/table&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;== Disease ==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[http://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN]] Defects in FGFR2 are the cause of Crouzon syndrome (CS) [MIM:[http://omim.org/entry/123500 123500]]; also called craniofacial dysostosis type I (CFD1). CS is an autosomal dominant syndrome characterized by craniosynostosis (premature fusion of the skull sutures), hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; [:]&amp;lt;ref&amp;gt;PMID:7581378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7987400&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7655462&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8946174&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8956050&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9152842&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9521581&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10574673&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11380921&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Jackson-Weiss syndrome (JWS) [MIM:[http://omim.org/entry/123150 123150]]. JWS is an autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7874170&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8528214&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9385368&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Apert syndrome (APRS) [MIM:[http://omim.org/entry/101200 101200]]; also known as acrocephalosyndactyly type 1 (ACS1). APRS is a syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. &lt;/ins&gt;The &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations.&amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9677057&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7668257&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11390973&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719344&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9452027&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of Pfeiffer syndrome (PS) [MIM:[http://omim.org/&lt;/ins&gt;entry&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;/101600 101600]]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly. Three subtypes of Pfeiffer syndrome have been described: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).&amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8644708&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9002682&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11173845&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:11781872&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719333&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:7719345&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9150725&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9693549&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:9719378&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10394936&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10945669&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Beare-Stevenson cutis gyrata syndrome (BSCGS) [MIM:[http://omim.org/entry/123790 123790]]. BSCGS is an autosomal dominant condition is characterized by the furrowed skin disorder of cutis gyrata, acanthosis nigricans, craniosynostosis, craniofacial dysmorphism, digital anomalies, umbilical and anogenital abnormalities and early death.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8696350&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12000365&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of familial scaphocephaly syndrome (FSPC) [MIM:[http://omim.org/entry/609579 609579]]; also known as scaphocephaly with maxillary retrusion and mental retardation. FSPC is an autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17803937&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16061565&amp;lt;/ref&amp;gt;   Defects in FGFR2 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:[http://omim.org/entry/149730 149730]]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18056630&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16501574&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis (ABS2) [MIM:[http://omim.org/entry/207410 207410]]. A rare syndrome characterized by craniosynostosis, radiohumeral synostosis present from the perinatal period, midface hypoplasia, choanal stenosis or atresia, femoral bowing and multiple joint contractures. Arachnodactyly and/or camptodactyly have also been reported.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:10633130&amp;lt;/ref&amp;gt;   Defects in FGFR2 are the cause of Bent bone dysplasia syndrome (BBDS) [MIM:[http://omim.org/entry/614592 614592]]. BBDS is a perinatal lethal skeletal dysplasia characterized by poor mineralization of the calvarium, craniosynostosis, dysmorphic facial features, prenatal teeth, hypoplastic pubis and clavicles, osteopenia, and bent long bones. Dysmorphic facial features included low-set ears, hypertelorism, midface hypoplasia, prematurely erupted fetal teeth, and micrognathia.&amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:22387015&amp;lt;/ref&amp;gt;  &lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;== Function ==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[http://www.uniprot.org/uniprot/FGFR2_HUMAN FGFR2_HUMAN]] Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.&amp;lt;ref&amp;gt;PMID:8961926&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:8663044&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:12529371&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15190072&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:15629145&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16597617&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16844695&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17623664&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:17311277&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:18374639&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19410646&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19103595&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:21596750&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:19387476&amp;lt;/ref&amp;gt; &amp;lt;ref&amp;gt;PMID:16384934&amp;lt;/ref&amp;gt;  &lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;div style=&amp;quot;background-color:#fffaf0;&amp;quot;&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;== Publication Abstract from PubMed ==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Receptor tyrosine kinase (RTK) signaling is tightly regulated by protein allostery within the intracellular tyrosine kinase domains. Yet the molecular determinants of allosteric connectivity in tyrosine kinase domain are incompletely understood. By means of structural (X-ray and NMR) and functional characterization of pathogenic gain-of-function mutations affecting the FGF receptor (FGFR) tyrosine kinase domain, we elucidated a long-distance allosteric network composed of four interconnected sites termed the 'molecular brake', 'DFG latch', 'A-loop plug', and 'alphaC tether'. The first three sites repress the kinase from adopting an active conformation, whereas the alphaC tether promotes the active conformation. The skewed design of this four-site allosteric network imposes tight autoinhibition and accounts for the incomplete mimicry of the activated conformation by pathogenic mutations targeting a single site. Based on the structural similarity shared among RTKs, we propose that this allosteric model for FGFR kinases &lt;/ins&gt;is &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;applicable to other RTKs.&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Authors: Mohammadi, M&lt;/del&gt;., Chen&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;, &lt;/del&gt;H.&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases&lt;/ins&gt;.,Chen H&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;, Marsiglia WM, Cho MK, Huang Z, Deng J, Blais SP, Gai W, Bhattacharya S, Neubert TA, Traaseth NJ, Mohammadi M Elife&lt;/ins&gt;. &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;2017 Feb 6;6. pii: e21137. doi: 10.7554/eLife.21137. PMID:28166054&amp;lt;ref&amp;gt;PMID:28166054&amp;lt;/ref&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Description: Crystal Structure &lt;/del&gt;of &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;FGF Receptor 2 Tyrosine Kinase Domain Harboring &lt;/del&gt;the &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;D650V Activating Mutation&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;From MEDLINE&amp;amp;reg;/PubMed&amp;amp;reg;, a database &lt;/ins&gt;of the &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;U.S. National Library of Medicine.&amp;lt;br&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;[[Category&lt;/del&gt;: &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Unreleased Structures]]&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;/div&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Mohammadi, M&lt;/del&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;div class=&amp;quot;pdbe-citations 5ugl&amp;quot; style=&amp;quot;background-color&lt;/ins&gt;:&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;#fffaf0;&amp;quot;&amp;gt;&amp;lt;/div&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;== References ==&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;references/&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;__TOC__&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;&amp;lt;/StructureSection&amp;gt;&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Receptor protein-tyrosine kinase&lt;/ins&gt;]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen, H]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen, H]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Mohammadi, M]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Atp analoge]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Gain-of-function mutation]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Transferase]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Tyrosine kinase domain]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
			<pubDate>Sat, 11 Mar 2017 01:43:59 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:5ugl</comments>		</item>
		<item>
			<title>OCA at 21:56, 25 January 2017</title>
			<link>http://52.214.119.220/wiki/index.php?title=5ugl&amp;diff=2710500&amp;oldid=prev</link>
			<description>&lt;p&gt;&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 21:56, 25 January 2017&lt;/td&gt;
			&lt;/tr&gt;
		&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 3:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 3:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;The entry 5ugl is ON HOLD &lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;The entry 5ugl is ON HOLD &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Authors: Mohammadi, M., Chen, &lt;del style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;Huaibin&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Authors: Mohammadi, M., Chen, &lt;ins style=&quot;color: red; font-weight: bold; text-decoration: none;&quot;&gt;H.&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Description: Crystal Structure of FGF Receptor 2 Tyrosine Kinase Domain Harboring the D650V Activating Mutation&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;Description: Crystal Structure of FGF Receptor 2 Tyrosine Kinase Domain Harboring the D650V Activating Mutation&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Unreleased Structures]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Unreleased Structures]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt;-&lt;/td&gt;&lt;td style=&quot;background: #ffa; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen, Huaibin]]&lt;/div&gt;&lt;/td&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Mohammadi, M]]&lt;/div&gt;&lt;/td&gt;&lt;td class='diff-marker'&gt; &lt;/td&gt;&lt;td style=&quot;background: #eee; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Mohammadi, M]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot;&gt;&amp;nbsp;&lt;/td&gt;&lt;td class='diff-marker'&gt;+&lt;/td&gt;&lt;td style=&quot;background: #cfc; color:black; font-size: smaller;&quot;&gt;&lt;div&gt;[[Category: Chen, H]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</description>
			<pubDate>Wed, 25 Jan 2017 21:56:57 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:5ugl</comments>		</item>
		<item>
			<title>OCA: Protected &quot;5ugl&quot; [edit=sysop:move=sysop]</title>
			<link>http://52.214.119.220/wiki/index.php?title=5ugl&amp;diff=2706882&amp;oldid=prev</link>
			<description>&lt;p&gt;Protected &amp;quot;&lt;a href=&quot;/wiki/index.php/5ugl&quot; title=&quot;5ugl&quot;&gt;5ugl&lt;/a&gt;&amp;quot; [edit=sysop:move=sysop]&lt;/p&gt;

			&lt;table style=&quot;background-color: white; color:black;&quot;&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;col class='diff-marker' /&gt;
			&lt;col class='diff-content' /&gt;
			&lt;tr&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;←Older revision&lt;/td&gt;
				&lt;td colspan='2' style=&quot;background-color: white; color:black;&quot;&gt;Revision as of 14:57, 18 January 2017&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;</description>
			<pubDate>Wed, 18 Jan 2017 14:57:56 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:5ugl</comments>		</item>
		<item>
			<title>OCA: New page: '''Unreleased structure'''  The entry 5ugl is ON HOLD   Authors: Mohammadi, M., Chen, Huaibin  Description: Crystal Structure of FGF Receptor 2 Tyrosine Kinase Domain Harboring the D650V A...</title>
			<link>http://52.214.119.220/wiki/index.php?title=5ugl&amp;diff=2706881&amp;oldid=prev</link>
			<description>&lt;p&gt;New page: '''Unreleased structure'''  The entry 5ugl is ON HOLD   Authors: Mohammadi, M., Chen, Huaibin  Description: Crystal Structure of FGF Receptor 2 Tyrosine Kinase Domain Harboring the D650V A...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;'''Unreleased structure'''&lt;br /&gt;
&lt;br /&gt;
The entry 5ugl is ON HOLD &lt;br /&gt;
&lt;br /&gt;
Authors: Mohammadi, M., Chen, Huaibin&lt;br /&gt;
&lt;br /&gt;
Description: Crystal Structure of FGF Receptor 2 Tyrosine Kinase Domain Harboring the D650V Activating Mutation&lt;br /&gt;
[[Category: Unreleased Structures]]&lt;br /&gt;
[[Category: Chen, Huaibin]]&lt;br /&gt;
[[Category: Mohammadi, M]]&lt;/div&gt;</description>
			<pubDate>Wed, 18 Jan 2017 14:57:55 GMT</pubDate>			<dc:creator>OCA</dc:creator>			<comments>http://52.214.119.220/wiki/index.php/Talk:5ugl</comments>		</item>
	</channel>
</rss>